Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

To evaluate the efficacy and safety of maintenance therapy with Adebrelimab plus Apatinib for extensive stage small cell lung cancer after first-line induction of Adebrelimab plus chemotherapy.

Participants needed: 38
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Yunpeng LiuUpdated: Jan 6, 2025Locations: 2
Eligibility criteria

Participants voluntarily enrolled in this study and signed an informed consent f... [+12]

Patients with meningeal metastases; [+20]

Read more
Status: Not yet recruiting

SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.

Participants needed: 28
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Yunpeng LiuUpdated: Oct 30, 2024Locations: 1
Eligibility criteria

Participants voluntarily enrolled in this study and signed an informed consent f... [+17]

Patients with meningeal metastases; Or patients with brain metastases that have... [+19]

Read more
Status: Not yet recruiting

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

Participants needed: 30
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Yunpeng LiuUpdated: Jun 18, 2024Locations: 1
Eligibility criteria

Age ≥18 and ≤75 years [+17]

Patients who have had other malignant tumors within the previous 5 years (except... [+13]

Read more